TI
RPRX

Trexquant Investment’s Repros Therapeutics Inc. RPRX Stock Holding History

Trexquant Investment’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-33,800
Closed -$251K – 1490
2015
Q3 		$251K Buy
+33,800
New +$258K 0.02% 923

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Trexquant Investment's RPRX Position: Q4 2015 in Review

Trexquant Investment sold out of Repros Therapeutics Inc. (RPRX) in Q4 2015, closing a stake of 33,800 shares — an estimated $251K sold.

Trexquant Investment first reported a position in RPRX in Q3 2015 and held it in 1 quarter. The position peaked at $251K in Q3 2015. 56 funds tracked by Wall St. Rank hold RPRX as of Q4 2015.

  • Trexquant Investment reported no remaining Repros Therapeutics Inc. position as of Q4 2015 after selling out during the quarter.
  • Trexquant Investment sold 33,800 Repros Therapeutics Inc. shares in Q4 2015, an estimated $251K.
  • Trexquant Investment first reported a position in Repros Therapeutics Inc. in Q3 2015 and held it in 1 quarter.
  • Trexquant Investment's Repros Therapeutics Inc. position peaked at $251K in Q3 2015.
  • 56 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2015.

Based on Trexquant Investment's 13F filing for Q4 2015, filed 10 Feb 2016.